Home | My Account | Online Store | Contact & Demand | Press Room | About Us | FAQs
Home
Buy & Subscribe
Special Features
Products & Services
Online Store
Products by category
Products by publisher
Product lines
News Channels
Biotechnology
Therapeutic Areas
Business
RSS Feeds
Free RSS News
Get the latest news direct
to your desktop
feed image

Search in our News Channels

Cheap OEM Software
  

Search in our Online Store
Oncology
Filter     Order     Display # 
Date Item Title
01 Apr 2006 OncoTherapy Science, Fuso Pharmaceutical Industries Jointly Undertake Phase I Clinical Trial of Anglogenesis Inhibitor OTS102
31 Mar 2006 Hana Biosciences Initiates Talotrexin Phase II Clinical Trials in Relapsed or Refractory Non-Small Cell Lung Cancer (NSCLC
31 Mar 2006 Medarex Announces Initiation of Registrational Trial for Ipilimumab (MDX-010) as Monotherapy in Previously-Treated Metastatic Melanoma Patients
31 Mar 2006 Cytokinetics Reports Data for Ispinesib (SB-715992) in Platinum-Sensitive Non-Small Cell Lung Cancer
31 Mar 2006 Epicept Announces Publication Of Phase III Ceplene Study Results For Acute Myeloid Leukemia
31 Mar 2006 Pharmion Corporation Announces Submission of Vidaza NDA Supplement for IV Administration
30 Mar 2006 Amgen and Abgenix Complete Biologics License Application for FDA Approval of Panitumumab
30 Mar 2006 Genentech and Biogen Idec Submit Supplemental Biologics License Application for First-Line Use of Rituxan in Low-Grade or Follicular CD20-Positive B-Cell Non-Hodgkin’s Lymphoma
30 Mar 2006 Ameripath Announces Advanced Testing For Myeloproliferative Disorders
29 Mar 2006 Yale researchers find phenoxodiol restores sensitivity to chemo in some women with ovarian cancer
29 Mar 2006 GenVec Begins Phase II Melanoma Study with TNFerade™
29 Mar 2006 CuraGen and TopoTarget Announce Initiation of First NCI-sponsored Clinical Trial with PXD101
29 Mar 2006 PhotoCure - Efficient cancer gene therapy induced by the PCI technology
29 Mar 2006 Adherex Receives Regulatory Clearance For Phase II Weekly Dosing Schedule
28 Mar 2006 Gentium Receives First IRB Approval to Begin U.S. Phase III Trial with Defibrotide to Treat Veno-Occlusive Disease with Multiple-Organ Failure
28 Mar 2006 Diatos Announces Expansion of Medarex Cancer Product Licensing Agreement
28 Mar 2006 YM BioSciences' partner, Oncoscience AG, cleared for Phase III trial in Germany with nimotuzumab
28 Mar 2006 SGX Pharmaceuticals Announces Strategic Collaboration to Develop and Commercialize BCR-ABL Inhibitors for the Treatment of Chronic Myelogenous Leukemia (CML)
25 Mar 2006 Antigenics Reports Phase 3 Results for Oncophage in Kidney Cancer
25 Mar 2006 Taxotere® Receives Positive Opinion From The Committee For Medicinal Products For Human Use Recommending Approval In The European Union For Metastatic Stomach Cancer
25 Mar 2006 CancerVax Announces Results of Phase 3 Clinical Trials of Canvaxin(TM) in Patients With Stage III and Stage IV Melanoma
25 Mar 2006 BSD Medical Applies for FDA Approval of the BSD-2000 Cancer Treatment System
25 Mar 2006 SD Pharmaceuticals Inc. Reports Positive Efficacy Data on Its Non-Immunogenic Paclitaxel Formulation
24 Mar 2006 TAXOTERE(R) Receives U.S. FDA Approval For Use In Advanced Stomach Cancer
24 Mar 2006 Algeta publish results of new thorium-227 mAb conjugate
24 Mar 2006 OXiGENE Completes Patient Enrollment In A Phase II Clinical Trial Evaluating CA4P With Chemotherapy In Imageable Solid Tumors
24 Mar 2006 Genta and Emisphere Technologies Enter into Exclusive Worldwide Licensing Agreement for Development of an Oral Gallium Compound
24 Mar 2006 New Clinical Data Show Benefits of Femara(R) for Women With Breast Cancer Even After Prolonged Period of no Anti-Cancer Treatment Post tamoxifen
24 Mar 2006 YM Biosciences Initiates Non-Small-Cell Lung Cancer Trial With Nimotuzumab
23 Mar 2006 Pixantrone Combination Regimen Produces High Rates of Complete Remission for Patients With Aggressive NHL Who Fail CHOP Therapy
23 Mar 2006 Entremed Presents Preclinical Data Supporting 2ME2’s DMARD Activity In Rheumatoid Arthritis
23 Mar 2006 TopoTarget and CuraGen initiate Phase Ib/II trial with PXD101 in combination with Velcade for Multiple Myeloma
23 Mar 2006 GammaCan Announces Positive Pre-IND Meeting with the U.S. FDA Regarding VitiGam - the Company's Novel Treatment for Metastatic Malignant Melanoma
21 Mar 2006 Orphan Drug Designation Granted by the U.S. FDA for Ceflatonin®
20 Mar 2006 SciClone's ZADAXIN Granted Orphan Drug Designation for Malignant Melanoma in United States
20 Mar 2006 Sunesis Pharmaceuticals Initiates Phase II Clinical Trial of SNS-595 in Small Cell Lung Cancer
20 Mar 2006 Spectrum Pharmaceuticals to Acquire NDA for an Oncology Drug and other Assets
20 Mar 2006 Antisoma’s phase II study of AS1404 in ovarian cancer completes recruitment
20 Mar 2006 Femara® approved in Germany as initial therapy for postmenopausal women with early breast cancer after surgery
17 Mar 2006 Inex Pharmaceuticals Licenses Three Targeted Chemotherapy Products to Hana Biosciences
17 Mar 2006 Wyeth Pharmaceuticals Announces Termination of Phase 3 Clinical Program with Oral Temsirolimus in Women with Metastatic Breast Cancer
17 Mar 2006 Phase I/II Clinical Data Demonstrate Safety and Antitumor Activity of Introgen's ADVEXIN(R) in Patients With Advanced Esophageal Cancer
17 Mar 2006 LymphoSign Inc. Completes Successful Pre-clinical Testing of Promising New Leukemia Drug
15 Mar 2006 Genvec Expands TNFerade Phase II Pancreatic Cancer Study Into Phase II/III Trial
14 Mar 2006 Arrowhead Research Subsidiary, Insert Therapeutics, Receives FDA Approval for IT-101 Phase I Clinical Trial; Clinical Trials for Patented Nanotechnology-Based Therapeutic Set to Begin
14 Mar 2006 Spectrum Pharmaceuticals Advances EOquin(TM) Towards Registration & Expects to Initiate Phase 3 Study In 2006
14 Mar 2006 SuperGen Announces Results From Combination Study in CLL Published in the Journal of Clinical Oncology
14 Mar 2006 SDSU Study Shows Antibody May Reduce or Eliminate Tumors
10 Mar 2006 Epigenomics Confirms Lead Marker for Prediction of Breast Cancer Relapse
10 Mar 2006 Braintree Laboratories, Inc. In-Licenses Global Rights To Oncology Drug Platform
 
<< Start < Prev 51 52 53 54 55 56 Next > End >>
Results 2551 - 2600 of 2757

PipelineReview.com is powered by La Merie Business Intelligence La Merie Business Intelligence

For immediate assistance, please call us during business hours: Mon-Fri 09:00am - 18:30pm; GMT+01

La Merie S.L | Passatge Jordi Ferran, 20 | E-08028 Barcelona | T +34 93 342 91 97 | F +34 93 342 91 98 | Email info@lamerie.com | Internet www.lamerie.com
All contents © by La Merie S. L

Competitor Analysis Series

Diabetes Drug Pipeline

Order Now

Brief Report Series

CD40 and CD40L (CD154) Agonists & Antagonists

Order Now

Subscribe La Merie Biologics